Farma Mondo Group Expands Existing Partnership with Recordati Rare Diseases, Signing Exclusive Agreement to Distribute Enjaymo (Sultimlimab-jome) in countries where the product is not commercially available.
CHIASSO, Switzerland and London – July 24th, 2025 – Farma Mondo Group announced today the signing of an exclusive distribution agreement with Recordati Rare Diseases to distribute Enjaymo (sutimlimab-jone). The agreement covers various emerging markets across LATAM, APAC, and Russia-CIS.
Farma Mondo is a Swiss-based pharmaceutical group acting as a commercial partner for innovative and specialty medicines in emerging and complex markets. Recordati Rare Diseases is a dedicated business unit focused on rare diseases within the Recordati Group, and since 2007 has had a mission to ‘Focus on the Few’ and reduce the impact of rare and devastating diseases by providing urgently needed medicines.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: We are excited to be partnering once again with Recordati for their newly acquired cutting edge therapy and working together towards bringing hope for patients where no else does. This collaboration reinforces FarmaMondo’s capabilities to enhance and expand the reach of innovative therapies while complementing our partners existing global commercial strategies.
About Enjaymo
Enjaymo (Sultimlimab-jome) is the first and only FDA/EMA approved treatment for people with cold agglutinin disease (CAD)
ENJAYMO is a prescription medicine used to treat hemolysis in adults living with CAD.
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group committed to providing healthcare professionals and the patients they care for with commercial access to innovative medicines. Farma Mondo offers biopharmaceutical innovators a high-value, end-to-end commercialization partnership in emerging markets, based on our unique expertise and geographic footprint, and aimed at providing patients with access to innovative specialty medicines. FarmaMondo serves as a one-stop commercial partner, providing access to key emerging markets through a single Swiss-based relationship and 14 operational locations.
About Recordati
Recordati is an international pharmaceutical, uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,580 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.
